Despite lapatinib (LAP) being a small-molecule tyrosine kinase inhibitor with high levels of effectiveness and limited side effects for treating HER2-positive BC (Rusnak et al., 2001; Chan, 2006), innate or acquired LAP resistance has led to an obstacle for BC therapy (Liu et al., 2009; Wang et al., 2011). This evidence concerns the gene ERBB2 and breast cancer.